Publications by authors named "V S S Attili"

Background Early inflammatory lesions of lichen sclerosus are histopathologically difficult to diagnose until the hallmark of the disease i.e., papillary sclerosis becomes visible in histological sections.

View Article and Find Full Text PDF
Article Synopsis
  • BCD-020 is a proposed biosimilar to rituximab, demonstrating similar quality and effectiveness in treating adult patients with indolent lymphomas in a multicenter clinical trial.
  • The study involved 174 patients, showing overall response rates of 44.71% for BCD-020 and 41.89% for rituximab, indicating equivalent efficacy between the two treatments.
  • Both drugs had comparable safety profiles, with no unexpected adverse reactions and similar patterns in the depletion of B-cells, confirming pharmacokinetic equivalence.
View Article and Find Full Text PDF

The interplay between host immunity and tumour cells has opened the possibility of targeting tumour cells by modulation of the human immune system. Cancer immunotherapy involves the treatment of a tumour by utilizing the recombinant human immune system components to target the pro-tumour microenvironment or by revitalizing the immune system with the ability to kill tumour cells by priming the immune cells with tumour antigens. In this review, current immunotherapy approaches to cancer with special focus on dendritic cell (DC)-based cancer vaccines are discussed.

View Article and Find Full Text PDF

This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy).

View Article and Find Full Text PDF